SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Big pharma more open to strong relationships, less heavy handed

By Nick Taylor & Claire Videau , 03-Feb-2011
Last updated the 03-Feb-2011 at 11:50 GMT

Big pharma more open to strong relationships, less heavy handed
Big pharma more open to strong relationships, less heavy handed
Loading...

Big pharma has taken a less heavy handed approach to relationships as cutbacks have made outsourcing key, according to Stephen Munk, CEO of Ash Stevens.

In the past Ash Stevens was competing with in-house big pharma capacity, said Munk, but the need to trim operations has shifted the environment. This has been accompanied by a change in attitude, with big pharma becoming less heavy handed and more open to strong relationships.

Typically Ash Stevens will establish a prime contact who acts as “a weaver of the entire fabric of the process”. This ensures one point of contact understands all elements of the project, from engineering requirements to regulatory affairs.

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO Agneta Bergvall says drugmakers' efforts to make pharmaceutical manufacturing green are worth...

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Will Downie

Senior VP Global Vusiness Development & Marketing, Catalent

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

Quincy Mattingly

Regional Manager, AlpVision

Cobra Biologics talks recent fill finish acquisition and future growth plans

Cobra Biologics talks recent fill finish acquisition and future growth plans

Philip Ridley-smith

Business Development & Marketing Manager, Cobra Biologics

Catalent says sharing with industry will not dull competetive edge

Catalent says sharing with industry will not dull competetive edge

Kurt Nielsen and Cornell Stamoran

Various, Catalent

Bend Research hunting new partnerships to boost bioavailability offering

Bend Research hunting new partnerships to boost bioavailability offering

David Lyon and Karen Coppens

Various, Bend Research and Dow

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Andrea Schiefer

VP of European clinical operations and executive director of pharmacovigilance,...

Home visits = regulatory thumbs up? ResearchNurses.co thinks so

Home visits = regulatory thumbs up? ResearchNurses.co thinks so

Sue Mackay

Research nursing team manager, ResearchNurses.co

Consolidation prevalent in industry, says third largest CMO

Consolidation prevalent in industry, says third largest CMO

Brad Carlson

VP Marketing 7 Sales, Aenova

Catalent commits to ADCs by upping its stake in Redwood

Catalent commits to ADCs by upping its stake in Redwood

Aileen Ruff

Global Strategic Marketing Director, Biologics and Sterile Technologies at Catalent...

Kemwell Talks Expansion and Approvals in India and the US

Kemwell Talks Expansion and Approvals in India and the US

Christian Ahlmark

Director of Corporate Development , Kemwell Biopharma

AMRI Exec Discusses 'New Bar' in FDA Enforcement

Following the completion of remediation efforts to deal with an FDA warning letter, Chris...

Happy holidays from William Reed Business Media!

Happy holidays from William Reed Business Media!

The working year is almost done, time to pause from ‘the business’ and embrace...

Aesica says academic partnerships are key for CMOs

Aesica says academic partnerships are key for CMOs

Alan Raymond

Sales & Marketing Director, Aesica Pharmaceuticals

Wockhardt targets CMO space for diversification

Wockhardt targets CMO space for diversification

Tom Salus

Associate Vice President, Business Development - Contract Services, Wockhardt

Kemwell and Boehringer set to finish biologics plant in India

Kemwell and Boehringer set to finish biologics plant in India

Christian Ahlmark

Director of corporate development , Kemwell